Kidney Disease Clinical Trials in Chicago

Showing 281-300 of 484 trials

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

NCT03308396

This is a single arm, multi-centre (via Big Ten Cancer Research Consortium) phase Ib/II study of patients treated with durvalumab 1500 mg IV q 4 weeks in combination with guadecitabine at the recommended phase 2 dose subcutaneously for 5 consecutive days. Eligible patients will have metastatic RCC with a clear cell component, ECOG performance status of 0-1, have received 0-1 prior therapy but no prior anti-PD-1/PD-L1/CTLA4 (Cohort 1, 36 subjects). Study treatment could potentially continue for up to 13 cycles (52 weeks).

Advanced Kidney CancerKidney CancerClear Cell Renal Cell Carcinoma

Ajjai Alva, MD57 participantsStarted Dec 2017

Chicago, Illinois, United States • Iowa City, Iowa, United States • Ann Arbor, Michigan, United States +2 more locations

COMPLETEDPhase 1/22.2 miles

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

NCT02178722

The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.

Microsatellite-instability (MSI) High Colorectal Cancer (CRC)Endometrial CancerHead and Neck Cancer+11 more

Incyte Corporation444 participantsStarted Jul 2014

La Jolla, California, United States • Los Angeles, California, United States • Sacramento, California, United States +21 more locations

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Kidney Disease Trials in Other Cities

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery

Safety Study of MGA271 in Refractory Cancer

Phase I Biomarker Study (BMS-936558)

Tolvaptan Extension Study in Participants With ADPKD

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

Fenestrated AAA Endovascular Graft Post-Approval Study

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Effect of Lost Wage Reimbursement to Kidney Donors on Living Donation Rates

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

A Cross-Sectional Study to Assess Walking Performance in Subjects With Peripheral Artery and End Stage Kidney Disease

Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal Failure

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Other Conditions in Chicago